A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.

Authors

Peter M Voorhees
Douglas W Sborov
Jacob Laubach
Jonathan L Kaufman
Brandi Reeves
Cesar Rodriguez
Rebecca Silbermann
Luciano J Costa
Larry D Anderson
Nitya Nathwani
Nina Shah
Naresh Bumma
Yvonne A Efebera, OhioHealth
Sarah A Holstein
Caitlin Costello
Andrzej Jakubowiak
Tanya M Wildes
Robert Z Orlowski
Kenneth H Shain
Andrew J Cowan
Shira Dinner
Katharine S Gries
Huiling Pei
Annelore Cortoos
Sharmila Patel
Thomas S Lin
Saad Z Usmani
Paul G Richardson

Document Type

Article

Publication Title

Future oncology

First Page

25

Last Page

49

DOI

10.1080/14796694.2024.2408909

Publication Date

1-1-2025

Recommended Citation

Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma. Future Oncol. 2025 Jan;21(1):25-49. doi: 10.1080/14796694.2024.2408909. Epub 2024 Oct 25. PMID: 39452950; PMCID: PMC11789466.